Endocrine and Neuroendocrine Tumors

The certified Interdisciplinary Endocrine and Neuroendocrine Tumor (IENET) center of the UCT Mainz is one of only six Centers of Excellence in Germany and one of 25 centers in Europe for the diagnosis and therapy of patients with neuroendocrine tumors. In 2014, a total number of 248 patients with NET have been treated at the UCT/IENET center (112 patients with newly diagnosed NETs) and 378 patients have been discussed in the weekly tumor conference. A total number of 1,096 PETs (PET in NET: 139) have been performed, 36 patients underwent Peptide Receptor Radionuclide Therapy and 360 patients hepato-biliary and / or 190 pancreatic surgeries. Further, 220 transarterial chemoembolisations were performed demonstrating the importance of multidisciplinary care for this rare tumor entity.

Clinical Research

The UCT/IENET center contributed to the majority of relevant clinical trials in the field of NET treatment (e.g. RADIANT-2 trial Lancet 2011; CLARINET trial, N Engl J Med 2014) and more than 25% of all NET patients have been treated in one of 8 prospective clinical phase II-IV trials.

Most significant publications

• Caplin M.E., M. Pavel, J.B. Ćwikła, A.T. Phan, M. Raderer, E. Sedláčková, G. Cadiot, E.M. Wolin, J. Capdevila, L. Wall, G. Rindi, A. Langley, S. Martinez, J. Blumberg, P. Ruszniewski CLARINET Investigators. 2014. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 371(3):224-33.
   
• Pavel M.E., J.D Hainsworth, E. Baudin, M. Peeters, D. Hörsch, R.E. Winkler, J. Klimovsky, D. Lebwohl, V. Jehl, E.M. Wolin, K. Oberg, E. Van Cutsem, J.C. Yao; RADIANT-2 Study Group. 2011. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 378(9808):2005-12.